_version_ 1784600422185435136
author Galluppi, Gerald R.
Brar, Satjit
Caro, Luzelena
Chen, Yuan
Frey, Nicolas
Grimm, Hans Peter
Rudd, Deanne Jackson
Li, Chi‐Chung
Magee, Mindy
Mukherjee, Arnab
Nagao, Lee
Purohit, Vivek S.
Roy, Amit
Salem, Ahmed Hamed
Sinha, Vikram
Suleiman, Ahmed A.
Taskar, Kunal S.
Upreti, Vijay V.
Weber, Benjamin
Cook, Jack
author_facet Galluppi, Gerald R.
Brar, Satjit
Caro, Luzelena
Chen, Yuan
Frey, Nicolas
Grimm, Hans Peter
Rudd, Deanne Jackson
Li, Chi‐Chung
Magee, Mindy
Mukherjee, Arnab
Nagao, Lee
Purohit, Vivek S.
Roy, Amit
Salem, Ahmed Hamed
Sinha, Vikram
Suleiman, Ahmed A.
Taskar, Kunal S.
Upreti, Vijay V.
Weber, Benjamin
Cook, Jack
author_sort Galluppi, Gerald R.
collection PubMed
description
format Online
Article
Text
id pubmed-8596613
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85966132021-12-02 Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program Galluppi, Gerald R. Brar, Satjit Caro, Luzelena Chen, Yuan Frey, Nicolas Grimm, Hans Peter Rudd, Deanne Jackson Li, Chi‐Chung Magee, Mindy Mukherjee, Arnab Nagao, Lee Purohit, Vivek S. Roy, Amit Salem, Ahmed Hamed Sinha, Vikram Suleiman, Ahmed A. Taskar, Kunal S. Upreti, Vijay V. Weber, Benjamin Cook, Jack Clin Pharmacol Ther Perspectives John Wiley and Sons Inc. 2021-05-15 2021-11 /pmc/articles/PMC8596613/ /pubmed/33991429 http://dx.doi.org/10.1002/cpt.2265 Text en © 2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Perspectives
Galluppi, Gerald R.
Brar, Satjit
Caro, Luzelena
Chen, Yuan
Frey, Nicolas
Grimm, Hans Peter
Rudd, Deanne Jackson
Li, Chi‐Chung
Magee, Mindy
Mukherjee, Arnab
Nagao, Lee
Purohit, Vivek S.
Roy, Amit
Salem, Ahmed Hamed
Sinha, Vikram
Suleiman, Ahmed A.
Taskar, Kunal S.
Upreti, Vijay V.
Weber, Benjamin
Cook, Jack
Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program
title Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program
title_full Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program
title_fullStr Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program
title_full_unstemmed Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program
title_short Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program
title_sort industrial perspective on the benefits realized from the fda’s model‐informed drug development paired meeting pilot program
topic Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596613/
https://www.ncbi.nlm.nih.gov/pubmed/33991429
http://dx.doi.org/10.1002/cpt.2265
work_keys_str_mv AT galluppigeraldr industrialperspectiveonthebenefitsrealizedfromthefdasmodelinformeddrugdevelopmentpairedmeetingpilotprogram
AT brarsatjit industrialperspectiveonthebenefitsrealizedfromthefdasmodelinformeddrugdevelopmentpairedmeetingpilotprogram
AT caroluzelena industrialperspectiveonthebenefitsrealizedfromthefdasmodelinformeddrugdevelopmentpairedmeetingpilotprogram
AT chenyuan industrialperspectiveonthebenefitsrealizedfromthefdasmodelinformeddrugdevelopmentpairedmeetingpilotprogram
AT freynicolas industrialperspectiveonthebenefitsrealizedfromthefdasmodelinformeddrugdevelopmentpairedmeetingpilotprogram
AT grimmhanspeter industrialperspectiveonthebenefitsrealizedfromthefdasmodelinformeddrugdevelopmentpairedmeetingpilotprogram
AT rudddeannejackson industrialperspectiveonthebenefitsrealizedfromthefdasmodelinformeddrugdevelopmentpairedmeetingpilotprogram
AT lichichung industrialperspectiveonthebenefitsrealizedfromthefdasmodelinformeddrugdevelopmentpairedmeetingpilotprogram
AT mageemindy industrialperspectiveonthebenefitsrealizedfromthefdasmodelinformeddrugdevelopmentpairedmeetingpilotprogram
AT mukherjeearnab industrialperspectiveonthebenefitsrealizedfromthefdasmodelinformeddrugdevelopmentpairedmeetingpilotprogram
AT nagaolee industrialperspectiveonthebenefitsrealizedfromthefdasmodelinformeddrugdevelopmentpairedmeetingpilotprogram
AT purohitviveks industrialperspectiveonthebenefitsrealizedfromthefdasmodelinformeddrugdevelopmentpairedmeetingpilotprogram
AT royamit industrialperspectiveonthebenefitsrealizedfromthefdasmodelinformeddrugdevelopmentpairedmeetingpilotprogram
AT salemahmedhamed industrialperspectiveonthebenefitsrealizedfromthefdasmodelinformeddrugdevelopmentpairedmeetingpilotprogram
AT sinhavikram industrialperspectiveonthebenefitsrealizedfromthefdasmodelinformeddrugdevelopmentpairedmeetingpilotprogram
AT suleimanahmeda industrialperspectiveonthebenefitsrealizedfromthefdasmodelinformeddrugdevelopmentpairedmeetingpilotprogram
AT taskarkunals industrialperspectiveonthebenefitsrealizedfromthefdasmodelinformeddrugdevelopmentpairedmeetingpilotprogram
AT upretivijayv industrialperspectiveonthebenefitsrealizedfromthefdasmodelinformeddrugdevelopmentpairedmeetingpilotprogram
AT weberbenjamin industrialperspectiveonthebenefitsrealizedfromthefdasmodelinformeddrugdevelopmentpairedmeetingpilotprogram
AT cookjack industrialperspectiveonthebenefitsrealizedfromthefdasmodelinformeddrugdevelopmentpairedmeetingpilotprogram